Insider at Acumen Pharmaceuticals (ABOS) files to sell 2,671 shares

Rhea-AI Filing Summary

Acumen Pharmaceuticals, Inc. insider plans to sell additional common stock under Rule 144. A notice covers the proposed sale of 2,671 shares of common stock through Merrill Lynch on 01/28/2026, with an aggregate market value of $8,017.29. The shares relate to an employee stock option exercise on the same date via a broker-assisted cashless transaction.

The filing also lists prior sales of Acumen Pharmaceuticals common stock by Derek Meisner over the past three months, including 4,000 shares for $7,838.00 on 01/05/2026 and 10,898 shares for $21,437.56 on 01/06/2026. Company shares outstanding are stated as 60,573,425, providing context for these transactions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	2671	8017.29	60573425	01/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/28/2026	Exercise of employee stock options	Acumen Pharmaceuticals, Inc.			2671	01/28/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7838.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	10898	21437.56
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	11770	23414.63
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/08/2026	36911	67244.23
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/09/2026	5200	9169.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/12/2026	8548	14658.02
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/21/2026	2247	4063.33
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/22/2026	1054	1939.36
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/23/2026	5633	10492.83
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/26/2026	15085	45262.48

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Acumen Pharmaceuticals (ABOS) Form 144 filing disclose?

The Form 144 notice discloses a planned sale of 2,671 Acumen Pharmaceuticals common shares. These shares stem from an employee stock option exercise and are to be sold through Merrill Lynch on 01/28/2026 under Rule 144 resale provisions.

How many Acumen Pharmaceuticals (ABOS) shares are planned for sale?

The filing covers a proposed sale of 2,671 shares of Acumen Pharmaceuticals common stock. The aggregate market value for this contemplated transaction is reported as $8,017.29, with the sale expected to occur on 01/28/2026 through Merrill Lynch.

How were the ABOS shares in this Form 144 acquired?

The 2,671 Acumen Pharmaceuticals shares were acquired on 01/28/2026 through an exercise of employee stock options. The transaction used a broker-assisted cashless exercise, meaning the broker handled the sale of shares to cover the exercise cost.

What prior ABOS stock sales by this insider are listed?

The notice lists several prior sales of Acumen Pharmaceuticals common stock over three months. Examples include 4,000 shares for $7,838.00 on 01/05/2026 and 10,898 shares for $21,437.56 on 01/06/2026, all attributed to Derek Meisner.

Which broker is handling the planned ABOS share sale?

Merrill Lynch, located at 225 Liberty Street, Floor 37, New York, NY 10281, is identified as the broker. The firm is listed to handle the planned sale of 2,671 Acumen Pharmaceuticals common shares on or about 01/28/2026 on the NASDAQ exchange.

How many Acumen Pharmaceuticals (ABOS) shares are outstanding?

The filing reports 60,573,425 Acumen Pharmaceuticals common shares outstanding. This figure offers context for the planned 2,671-share sale and the recent series of insider transactions disclosed over the past three months in the same notice.